Dr Reddy’s partners with Gland Pharma to market 8 ANDAs in US

The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the U.S.

The combined sale of branded and generic versions of the products in the U.S. is approximately US$ 1 Billion MAT for the most recent twelve months ending in August 2016 according to IMS Health.

Alok Sonig, Executive Vice President and Head of North America, said: “We are excited about this opportunity. Dr. Reddy’s Laboratories has a strong track record in developing, marketing and distributing generic injectables in the U.S.

"Our strengths, combined with Gland’s track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term.”

Gland Pharma COO Srinivas Sadu said: “We are happy to expand our collaboration with Dr. Reddy’s for marketing and distribution of Gland Products in US and other Ex US markets.

Dr. Reddy’s has an impressive track record of commercializing injectables products in the U.S., and we are confident that our partnership will continue to grow.”

Dr. Reddy's is aggressively developing its US injectable business and recently launched Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar.